GlassScriptPhysician profile
Crystal Howlett
NPI 1659045805
$5,209.35
in general payments reported to CMS, 2019-2025
25 companies · $4,026 in 2025
The $4,026 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $348 · 2024: $835 · 2025: $4,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647 · Consulting Fee: $2,300 · Travel and Lodging: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.35 |
| Consulting Fee | $2,300.00 |
| Travel and Lodging | $262.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,619.19 | 2023-2025 | Mounjaro, Trulicity |
| Abbvie INC. | $460.05 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $413.87 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $198.28 | 2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $178.69 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $170.94 | 2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $162.42 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.73 | 2025 | Caplyta |
| Amgen INC. | $139.76 | 2025 | Otezla, Repatha |
| Astellas Pharma US INC | $91.33 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $87.39 | 2023-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $79.65 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $75.11 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $61.12 | 2025 | Acthar |
| Pfizer INC. | $45.60 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.39 | 2023 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $40.03 | 2025 | Auvelity |
| Medtronic, INC. | $37.43 | 2025 | Minimed 780g |
| Lundbeck LLC | $34.21 | 2025 | Rexulti |
| Verona Pharma, INC. | $31.05 | 2025 | Ohtuvayre |
| Ultragenyx Pharmaceutical INC. | $19.04 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $18.04 | 2024 | |
| Eisai INC. | $17.59 | 2024 | |
| Mimedx Group, INC. | $16.84 | 2024 | |
| Insulet Corporation | $14.60 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Howlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.